Validity and Feasibility of Newborn Bed Monitoring Device - a Clinical Pilot Study
Launched by ANNA AXELIN · Nov 5, 2024
Trial Information
Current as of August 23, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is testing a new bed monitoring device designed for newborns in hospitals. The goal is to see how well this device can track important information about babies, such as their heart rate, breathing, and movements while they sleep. The study will also look at how well the device can tell if a baby is awake or in different stages of sleep. Additionally, researchers want to find out how parents and healthcare professionals feel about using this device and what features are important for it to be useful in caring for newborns.
To participate in this study, newborns need to be healthy and stay in the newborn care area of the hospital, and parents must give their permission. Parents will be asked to fill out questionnaires and share their thoughts in interviews about how easy the device is to use. The newborns will be monitored while sleeping on the device for about two hours, and the results will be compared to a standard medical device to ensure accuracy. This trial is an important step in making sure the bed monitoring device is safe and effective for use in hospitals.
Gender
ALL
Eligibility criteria
- Inclusion Criteria for newborns:
- • received informed consent from both parents/guardians
- • newborn is treated in the Ward of families and newborns
- • newborn is having normal health status without ongoing additional treatments. No exclusion criteria
- Inclusion criteria for parents:
- • being a parent of newborn participating in the study with bed monitoring device
- • being able to participate in Finnish. No exclusion criteria
- Inclusion criteria for healthcare professionals:
- • being a healthcare professional working with newborns
- • being able to participate in Finnish. No exclusion criteria
About Anna Axelin
Anna Axelin is a distinguished clinical trial sponsor dedicated to advancing medical research through innovative and rigorous clinical studies. With a strong emphasis on patient-centered approaches, the organization aims to enhance therapeutic outcomes across various health conditions. Anna Axelin is committed to adhering to the highest ethical standards and regulatory guidelines, ensuring the integrity of trial data while prioritizing participant safety and well-being. Through collaboration with leading researchers and healthcare professionals, Anna Axelin strives to contribute valuable insights that drive the development of effective treatments and improve patient care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Turku, , Finland
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported